Abstract：
BACKGROUND: The aim of this study was to investigate the prognostic significance of the preoperative neutrophil-to-lymphocyte ratio in non-metastatic renal cell carcinoma.
METHODS: We retrospectively analyzed the records of patients with non-metastatic renal cell carcinoma who were operated between 2004 and 2020 at our institution. The Kaplan-Meier method was utilized to graphically display survivor functions. Univariate and multivariate Cox\'s proportional hazards regression models were utilized to analyze the association between neutrophil-to-lymphocyte ratio and oncological outcomes.
RESULTS: We included 202 patients. Patients with higher neutrophil-to-lymphocyte ratio had larger tumors (P=0.03), higher ASA score (P=0.014), clinical symptoms (P=0.04), sarcomatoid differentiation (P=0.03) and tumor necrosis (P=0.02). The rates of recurrence-free survival and metastasis-free survival were significantly lower in patients with a high neutrophil-to-lymphocyte ratio than in those with a low ratio (P=0.017; P=0.036 respectively). Multivariate analysis identified the neutrophil-lymphocyte ratio as an independent predictor of recurrence-free and metastasis-free survival (P=0.021; P=0.001 respectively).
CONCLUSIONS: A higher neutrophil-to-lymphocyte ratio has been associated with a symptomatic renal cancer with a significant prognostic factor for both recurrence-free and metastasis-free survival.
METHODS: 3.
METHODS: We retrospectively analyzed the records of patients with non-metastatic renal cell carcinoma who were operated between 2004 and 2020 at our institution. The Kaplan-Meier method was utilized to graphically display survivor functions. Univariate and multivariate Cox\'s proportional hazards regression models were utilized to analyze the association between neutrophil-to-lymphocyte ratio and oncological outcomes.
RESULTS: We included 202 patients. Patients with higher neutrophil-to-lymphocyte ratio had larger tumors (P=0.03), higher ASA score (P=0.014), clinical symptoms (P=0.04), sarcomatoid differentiation (P=0.03) and tumor necrosis (P=0.02). The rates of recurrence-free survival and metastasis-free survival were significantly lower in patients with a high neutrophil-to-lymphocyte ratio than in those with a low ratio (P=0.017; P=0.036 respectively). Multivariate analysis identified the neutrophil-lymphocyte ratio as an independent predictor of recurrence-free and metastasis-free survival (P=0.021; P=0.001 respectively).
CONCLUSIONS: A higher neutrophil-to-lymphocyte ratio has been associated with a symptomatic renal cancer with a significant prognostic factor for both recurrence-free and metastasis-free survival.
METHODS: 3.
摘要：
背景：本研究的目的是探讨术前中性粒细胞与淋巴细胞比值在非转移性肾细胞癌中的预后意义。
方法：我们回顾性分析了2004年至2020年间在我们机构接受手术的非转移性肾细胞癌患者的记录。Kaplan-Meier方法用于图形显示幸存者功能。单变量和多变量Cox比例风险回归模型用于分析中性粒细胞与淋巴细胞比值与肿瘤预后之间的关联。
结果：我们纳入了202例患者。中性粒细胞与淋巴细胞比率较高的患者肿瘤较大（P=0.03），较高的ASA评分（P=0.014），临床症状（P=0.04），肉瘤样分化（P=0.03）和肿瘤坏死（P=0.02）。中性粒细胞与淋巴细胞比率高的患者的无复发生存率和无转移生存率显着低于比率低的患者（P=0.017；P=0.036）。多因素分析确定中性粒细胞-淋巴细胞比率是无复发和无转移生存的独立预测因子(P=0.021;P=0.001)。
结论：较高的中性粒细胞与淋巴细胞比率与有症状的肾癌相关，是无复发和无转移生存的重要预后因素。
方法：3.
方法：我们回顾性分析了2004年至2020年间在我们机构接受手术的非转移性肾细胞癌患者的记录。Kaplan-Meier方法用于图形显示幸存者功能。单变量和多变量Cox比例风险回归模型用于分析中性粒细胞与淋巴细胞比值与肿瘤预后之间的关联。
结果：我们纳入了202例患者。中性粒细胞与淋巴细胞比率较高的患者肿瘤较大（P=0.03），较高的ASA评分（P=0.014），临床症状（P=0.04），肉瘤样分化（P=0.03）和肿瘤坏死（P=0.02）。中性粒细胞与淋巴细胞比率高的患者的无复发生存率和无转移生存率显着低于比率低的患者（P=0.017；P=0.036）。多因素分析确定中性粒细胞-淋巴细胞比率是无复发和无转移生存的独立预测因子(P=0.021;P=0.001)。
结论：较高的中性粒细胞与淋巴细胞比率与有症状的肾癌相关，是无复发和无转移生存的重要预后因素。
方法：3.
